SOLENO THERAPEUTICS INC
DelistedCIK 1484565fmd_01WBX1CPNDCMCNDD0ERXYAJJ3RManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Mar 31, 2026, 51 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | – | – | – | – | – | – | – | – | – |
| Cost of revenue | 2 | – | – | – | – | – | – | – | – | 3 |
| Gross profit | (0) | – | – | – | – | – | – | – | – | – |
| Research and development | 2 | 3 | 7 | 16 | 23 | 21 | 15 | 25 | 79 | 41 |
| Selling, general and administrative | 6 | 7 | – | – | – | – | – | 13 | 106 | 132 |
| Total operating expenses | 8 | 12 | 14 | 23 | 36 | 32 | 24 | 41 | 188 | 181 |
| Operating income | (8) | (12) | (14) | (23) | (36) | (32) | (24) | (41) | (188) | 9 |
| Interest expense | – | – | – | – | – | – | 0 | 0 | 0 | 5 |
| Interest and investment income | – | – | – | – | – | – | 0 | 3 | 12 | 17 |
| Other non-operating income (expense) | 2 | (1) | 2 | (7) | 12 | 1 | 0 | 2 | 12 | 11 |
| Income before taxes | (7) | (13) | (12) | (31) | (25) | (31) | (24) | (39) | (176) | 21 |
| Income tax expense | 0 | (2) | 0 | – | – | – | – | 0 | 0 | 0 |
| Net income from continuing operations | (7) | (12) | (12) | (31) | – | – | – | (39) | (176) | 21 |
| Net income | (12) | (15) | (13) | (31) | (25) | (31) | (24) | (39) | (176) | 21 |
| Net income to common shareholders | (16) | (16) | – | – | – | – | – | (39) | (176) | 20 |